Our company remains focused on advancing monoclonal antibody therapeutics for solid tumors, with a clear emphasis on combination immunotherapy strategies
After Phase 3 results show major hair regrowth gains
The approval was driven by data from the Phase III TULIP-SC trial
His appointment is expected to strengthen scientific input in policy discussions across public health, biotech, and translational research
The investigational therapy, MDX2003, is designed to go after cancer cells with a multi-pronged immune attack
IgAN is a rare, progressive kidney disease driven by abnormal IgA immune complexes that deposit in the kidneys
The start of our Phase 3 trial for an H5 influenza vaccine marks a significant milestone
The Phase III METEOROID study met its primary endpoint, with ENSPRYNG cutting the risk of a first relapse by 68% compared to placebo in adults and adolescents
The approval, following a positive recommendation from the European Medicines Agency’s CHMP, makes the vaccine valid across all 27 EU member states
The newly formed team is led by Tomabu Adjobimey, an immunologist known for his work in host-pathogen interactions and immune modulation
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
